GSK plc
Business Model Analysis
How GSK Makes Money
Annual Revenue: ~$43.1B
GSK generates revenue primarily through Pharmaceuticals & Biotechnology, with roughly ~$43.1B in annual revenue.
Core Growth Engine: Under Luke Miels, GSK is combining targeted acquisitions with faster R&D. Deals since 2025 include IDRx (GIST, January 2025), efimosfermin from Boston Pharmaceuticals ($1.2 billion upfront, July 2025) and Nuvalent ($10.6...
Revenue Model & Pricing
GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Its sales are reported in three groups. Specialty Medicines (~$17.8 billion (£13.5 billion) in 2025, about 41% of sales) covers HIV through ViiV Healthcare, respiratory and immunology biologics such as Nucala and Exdensur, and oncology drugs such as Jemperli, Ojjaara and Blenrep. Vaccines (~$12.1 billion (£9.2 billion), about 28%) are led by Shingrix for shingles, the Bexsero and Menveo meningitis vaccines and the Arexvy RSV vaccine. General Medicines (~$13.2 billion (£10.0 billion), about 31%) includes established inhalers such as Trelegy and Ventolin and antibiotics like Augmentin. GSK also earns royalty income on licensed products.
Core Revenue Streams
Specialty Medicines
~41%Specialty Medicines generated ~$17.8 billion (GBP 13.5 billion) in FY2025 sales, led by HIV, respiratory, immunology and inflammation, and oncology assets.
Vaccines
~28%Vaccines generated ~$12.1 billion (GBP 9.2 billion) in FY2025 sales, including Shingrix, meningitis vaccines, Arexvy, and other infectious-disease products.
General Medicines
~31%General Medicines generated ~$13.2 billion (GBP 10.0 billion) in FY2025 sales, with established respiratory, anti-infective, and other medicines providing cash flow and scale.
Growth Strategy
Under Luke Miels, GSK is combining targeted acquisitions with faster R&D. Deals since 2025 include IDRx (GIST, January 2025), efimosfermin from Boston Pharmaceuticals ($1.2 billion upfront, July 2025) and Nuvalent ($10.6 billion, completed July 2026). In July 2026 GSK identified 7 assets across 18 indications in oncology, respiratory, hepatology and vaccines to speed up, raised its 2026 phase III start target from 10 to more than 20, and launched a cost programme to fund that investment.
How GSK Makes Money: FAQ
What are the primary revenue streams generated by GSK plc?
GSK generates revenue through three core commercial segments: Vaccines (preventative pediatric, adolescent, and adult vaccines), Specialty Medicines (HIV therapeutics via ViiV Healthcare, oncology, immunology, and rare diseases), and General Medicines (inhaled respiratory therapies and mature established prescription pharmaceuticals).
How does ViiV Healthcare monetize long-acting injectable HIV therapies?
ViiV Healthcare monetizes long-acting HIV therapies like Cabenuva (monthly or bi-monthly treatment injection) and Apretude (bi-monthly prevention PrEP injection) through direct sales to specialty pharmacies, hospitals, and national health programs, capturing premium pricing over generic daily pills.
How does GSK distribute its vaccines to national immunization programs worldwide?
GSK distributes vaccines through government public health tenders, national immunization procurement agencies (such as the US CDC Vaccines for Children program, UK NHS, and Gavi, the Vaccine Alliance in developing nations), alongside private healthcare retail pharmacy networks.
What gross margin profile characterizes GSK's biopharmaceutical manufacturing model?
GSK delivers strong gross margins (typically 72% to 76%), driven by high-margin innovative vaccines (Shingrix, Arexvy), specialized HIV single-tablet and injectable regimens, efficient biologic cell-culture manufacturing, and strong patent exclusivity.
How does GSK manage the pricing and reimbursement of respiratory therapies like Trelegy Ellipta?
GSK contracts with pharmacy benefit managers (PBMs), health insurers, and government healthcare single-payer authorities, offering tiered rebates to secure preferred formulary placement for Trelegy Ellipta (the leading triple-combination inhaler for COPD and asthma).
What proportion of annual revenues does GSK reinvest into research and development (R&D)?
GSK reinvests approximately 18% to 20% of annual turnover into R&D (over $7.26 billion (£5.5 billion) to £6.0+ billion annually), funding advanced clinical trials, mRNA and adjuvant vaccine technologies, oncology antibody combinations, and functional genomics research.
What role do proprietary vaccine adjuvant platforms play in GSK's commercial moat?
GSK is a world leader in proprietary vaccine adjuvant systems (such as AS01B in Shingrix and Arexvy), which significantly enhance and prolong immune response in older adults and immunocompromised patients, creating high barriers to competitive entry.
How does GSK structure geographic sales across international markets?
GSK generates balanced global revenues: the United States represents approximately 50% to 52% of commercial sales, Europe accounts for 22% to 25%, and International/Emerging Markets (Japan, China, Latin America, Middle East) contribute the remaining 23% to 26%.
How does GSK make money?
Following a massive corporate restructuring, GSK now focuses entirely on complex biopharmaceuticals. They make massive billions from their global vaccines division (Shingrix for shingles), respiratory medicines, and their highly lucrative HIV division, ViiV Healthcare (which is actually a massive joint venture operated with Pfizer).
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Explore GSK
Core profile pages, founders and related research hubs for this company.